HOME >> BIOLOGY >> NEWS
UCSF-led study offers insight into cancer development, resistance to therapy: finding focuses on Ras oncogene

UCSF-led scientists have determined that under certain conditions the Ras oncogene, a key culprit in many cancers, suppresses the function of the p53 tumor-suppressor gene, offering an important insight into the development of some cancers, and an explanation for why some cancers are resistant to radiation therapy. The finding is published in the current issue of Cell.

The Ras gene is part of a molecular pathway that transmits messages for cell growth - an essential component of cell function - from the surface of the cell into the cell's nucleus. But when mutated, as it is in a third of cancers, Ras functions like a gas pedal jammed to the floor, driving a cell into growth and replication overdrive. If coupled with enough other mutations causing destabilization of the cell's growth controls, the Ras oncogene can contribute to the development of cancer.

While Ras's direct role in many cancers has been known, the new finding suggests that, by regulating the p53 tumor-suppressor gene, Ras may play an indirect role in many more, says the co-lead author of the study, Stefan Ries, PhD, a postdoctoral fellow in the laboratory of senior author Frank McCormick, PhD, director of the UCSF Comprehensive Cancer Center.

"Ras's suppression of p53 could play an important role in inactivating the tumor suppressor during the early stages of some tumor development. This may be particularly true in colon cancers," says Ries.

The p53 tumor-suppressor gene is one of several genes that serve as a protector of a cell's DNA. If DNA has been damaged, as can occur during DNA replication and cell division or as a result of an environmental injury, the gene receives a signal that it should halt the cell's cycle of growth. If the cell repairs itself, p53 releases its brake; but if the damage remains, p53 induces cell death, which prevents the cell from continued growth and, ultimately, the dividing into daughter cells containing its damaged DNA. Mutations are a form of DNA damag
'"/>

Contact: Jennifer O'Brien
jobrien@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
23-Oct-2000


Page: 1 2 3

Related biology news :

1. UCSF-led study raises doubts about marrow cell treatment for brain, heart
2. UCSF-led team reports new test improves detection of prions in animals
3. UCSF-led study points to pivotal, early event in cancer development
4. Student science contest participation influences study, career choices, alumni say
5. New study shows hope for treating inhalant abuse
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
8. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
11. Indiana University, EPA to study airborne PCBs

Post Your Comments:
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: ... at the following conferences, and invited investors to participate via ... Boston, MA Tuesday, March 3, 2015 at ... Conference, Orlando, FL Wednesday, March 4, ... Webcasts To access the live webcasts for these events, please ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet ... specializing in clinical study management systems, has recently ... , further distinguishing iMedNet ... Research Organizations (CROs) and healthcare consultants.  Building on ... prospective customer referrals and numerous co-marketing opportunities), MedNet,s ...
(Date:2/11/2015)... , February 11, 2015 ... report "Access Control Market by Product (Cards and Readers, ... Military and Defense, Government, Industrial, Healthcare, Education) and By ... by MarketsandMarkets, the Access Control Market is ... growing at a CAGR of 10.6% between ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
(Date:3/3/2015)... March 3, 2015  Rosa & Co. LLC, a ... and simulation research, today announced it has two posters ... for Clinical Pharmacology and Therapeutics meeting in ... Logo - http://photos.prnewswire.com/prnh/20150302/179058LOGO   ... a poster describing a quantitative systems pharmacology approach for ...
(Date:3/3/2015)... 03, 2015 Genedata, a leading ... and life science research, today announced that Pfizer ... platform for use at Pfizer biopharma research and ... is supporting Pfizer’s global deployment and roll out ... for Therapeutic Innovation (CTI), and Pharmaceutical Sciences groups. ...
(Date:3/3/2015)... 03, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Gene Therapy - ... , Gene therapy technologies are ... and cell therapy with genetically modified vectors. Gene ... and various routes of administration as well as ...
(Date:3/3/2015)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... on protecting the microbiome, announced today that Jeffrey Riley ... 27th Annual ROTH Conference being held on March 8-11, 2015 ... Dana Point, CA. Mr. Riley is ... p.m. (Pacific Time). A live webcast of Synthetic ...
Breaking Biology Technology:Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 2Rosa & Co. Announces Two Poster Presentations at the American Society for Clinical Pharmacology and Therapeutics 2015 Annual Meeting 3Genedata Biologics Licensed by Pfizer Inc. 2Genedata Biologics Licensed by Pfizer Inc. 3Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 2Gene Therapy Market Report 2014-2024 - Technologies, Markets and Companies 3Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
Cached News: